Healthcare diagnostics currently rely on mass spectrometry laboratories to determine the presence of certain diseases, typically taking days to complete while putting lives at risk. Recent studies have shown that some diseases can be detected by analyzing the volatile compounds in exhaled breath.

The BreathDetect 1000 is under development as the first bedside mass spectrometer that can provide immediate analysis, and is ideally suited for this application due to its laboratory-quality performance, rapid analysis, portability, and ease of use.

1ST Detect is currently working with the University of Texas Health Science Center at San Antonio to develop tests for various diseases. The technology has shown excellent results in immediately identifying several strains, which would reduce hospital stays and save lives.

The BreathDetect 1000 point‐of‐care bedside breathalyzer is being designed to detect various diseases that require immediate diagnosis within the hospital, doctor’s office or emergency vehicle.


  • Acute lung injury
  • Anti-microbial resistance
  • Constrictive bronchiolitis
  • Diabetes
  • Emerging infectious diseases
  • Influenza
  • Metals toxicology
  • Pneumonia
  • Pulmonary fibrosis
  • Respiratory health
  • Tuberculosis